Andrew Pollard is a Cardiology physician. OpenAlex indexes 46 publications with 1,358 citations (h-index 17); ClinicalTrials.gov lists 32 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
7502 State Rd Ste 2210
Cincinnati, OH 452552595
Telephone
513-421-3494Provider last certified this registry record 18 Nov 2025.
Clinical trials
- Combination Assessment Trial of COVID-19 Vaccines (COMBAT-COVID)
Sponsor: Aga Khan University Hospital, Pakistan
- A Study of a Candidate COVID-19 Vaccine (COV003)
Sponsor: University of Oxford
- Investigating a Vaccine Against COVID-19
Sponsor: University of Oxford
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
17 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Edwards Lifesciences CorporationProgram year20251 payment
- ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)Program year20256 payments
- Boston Scientific CorporationProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
80.4%Beta blocker18.5%Metoprolol Succinate53%Carvedilol26%Metoprolol Tartrate15%Propranolol Hcl Er5%Part D<11 patientsStatin16%Atorvastatin Calcium51%Rosuvastatin Calcium44%Simvastatin5%Part D<11 patients+ 13 more classes in this area
Blood & clotting
11.9%Factor Xa inhibitor7.6%Eliquis73%Xarelto27%Part D≥34 patientsP2Y12 inhibitor2.6%Clopidogrel100%Part D≥25 patients+ 1 more class in this area
Metabolism & gastrointestinal
7.7%SGLT2 inhibitor5.9%Jardiance100%Part D≥31 patientsPotassium supplement1.8%Potassium Chloride100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Sensor spacing affects the tissue impedance spectra of rabbit ventricular epicardium
American Journal of Physiology-Heart and Circulatory Physiology
2014
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”